# Advanced Chemotherapy Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/advanced-chemotherapy-technologies

- Industry: Medical Devices & Equipment
- Headquarters: Raleigh, US
- Website: www.advancedchemotech.com
- Total disclosed funding: $5.5M
- Latest round: Series A (Oct 29, 2020)
- Investors on record: 1

## About

Advanced Chemotherapy Technologies, Inc. is a US-based firm specializing in innovative strategies for drug delivery systems, primarily focused on enhancing chemotherapy effectiveness through advanced technologies.Founded in 2014 and headquartered in Raleigh, US, Advanced Chemotherapy Technologies, Inc. focuses on developing localized drug delivery systems for chemotherapy. The company has successfully completed 3 deals, with its most recent funding round occurring on August 11, 2021. This round involved a GRANT of USD 4.00 mn from the National Cancer Institute, raising the total amount raised to USD 2.50 mn. The founder, Joseph DeSimone, has a history of leadership in innovative technology development but does not have records of founding other companies.Advanced Chemotherapy Technologies, Inc. specializes in creating innovative drug delivery solutions that enhance the effectiveness of chemotherapy treatments. Its flagship product is the ACT-IOP-003, a localized drug delivery system designed to optimize chemotherapy administration and improve patient outcomes. The company serves a variety of healthcare sectors, providing cutting-edge solutions that have evolved significantly since their introduction.The company's revenue model is structured around various funding mechanisms, including grants. The recent GRANT funding of USD 4.00 mn will support the development of its products, ensuring ongoing financial support for its initiatives in the healthcare sector. As a pioneer in its field, the company maintains a strong focus on developing innovative solutions for chemotherapy delivery.Looking ahead, Advanced Chemotherapy Technologies, Inc. plans to advance the development of its ACT-IOP-003 drug delivery system, with the recent GRANT funding utilized specifically for this purpose. The company aims to expand its product offerings and explore new markets within North America and Europe by 2023, further enhancing its capabilities in cancer treatment solutions.

## Funding rounds

- Series A, Oct 29, 2020, $5.5M — Khosla Ventures

## Investors

- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A